GlassScriptPhysician profile
Anisha Jangi
NPI 1326230277
$1,548.11
in general payments reported to CMS, 2019-2025
20 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2021: $65.69 · 2022: $208 · 2023: $238 · 2024: $336 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $302.99 | 2021-2025 | Tecnis Iol, Catalys System |
| Alcon Vision LLC | $242.62 | 2019-2025 | Tryptyr, Eysuvis |
| Abbvie INC. | $225.88 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.04 | 2019 | |
| Carl Zeiss Meditec, INC. | $105.00 | 2019 | |
| Dompe US, INC. | $95.25 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $71.81 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $67.73 | 2023-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $46.24 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $34.21 | 2022-2024 | Ic-8 Apthera Iol |
| Lombart Brothers, INC. | $28.64 | 2021 | |
| Rayner Intraocular Lenses Limited | $28.43 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Halozyme INC | $26.76 | 2024 | Hylenex Recombinant |
| Sun Pharmaceutical Industries INC. | $25.52 | 2024 | |
| Aerie Pharmaceuticals, INC. | $23.11 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.48 | 2022 | |
| Eyepoint US, INC. | $16.65 | 2019 | |
| Biotissue Holdings INC. | $16.63 | 2022 | |
| Genzyme Corporation | $16.62 | 2025 | |
| Amgen INC. | $15.50 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Jangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.